| Print
Hansa Biopharma AB (HNSA)
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary,first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Hansa Biopharma AB First Quarter Earnings Results for 2027 | 2027-04-23T00:00:00 |
| Hansa Biopharma AB First Quarter Earnings Conference Call for 2027 | 2027-04-23T00:00:00 |
| Hansa Biopharma AB Annual Report for 2026 | 2027-03-26T00:00:00 |
| Hansa Biopharma AB Fourth Quarter Earnings Conference Call for 2026 | 2027-02-11T08:00:00 |
| Hansa Biopharma AB Fourth Quarter Earnings Results for 2026 | 2027-02-11T00:00:00 |
| Hansa Biopharma AB Third Quarter Earnings Result for 2026 | 2026-10-22T00:00:00 |
| Hansa Biopharma AB Third Quarter Earnings Conference Call for 2026 | 2026-10-22T00:00:00 |
| Hansa Biopharma AB Second Quarter Earnings Result for 2026 | 2026-07-16T00:00:00 |
| Hansa Biopharma AB Second Quarter Earnings Conference Call for 2026 | 2026-07-16T00:00:00 |
| Hansa Biopharma AB Annual General Meeting for 2026 | 2026-06-01T00:00:00 |
| Hansa Biopharma AB First Quarter Earnings Result for 2026 | 2026-04-23T00:00:00 |
| Hansa Biopharma AB First Quarter Earnings Conference Call for 2026 | 2026-04-23T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.